Halozyme Therapeutics Inc (NAS:HALO)
$ 61.49 0.51 (0.84%) Market Cap: 7.82 Bil Enterprise Value: 8.62 Bil PE Ratio: 20.36 PB Ratio: 17.27 GF Score: 90/100

Q2 2019 Halozyme Therapeutics Inc Earnings Call Transcript

Aug 06, 2019 / 08:30PM GMT
Release Date Price: $17.15 (+1.48%)
Operator

Good afternoon, everyone. I would now like to turn the conference over to Al Kildani, Vice President of Investor Relations and Corporate Communications for Halozyme Therapeutics.

Mr. Kildani, please begin.

Albert S. Kildani;
Halozyme Therapeutics, Inc. - VP of IR & Corporate Communications

Good afternoon, and welcome to our second quarter 2019 financial results conference call. In addition to our press release issued today after the close, you can find a supplementary slide presentation that will be referenced on today's call in the Investor Relations section of our website.

Leading the call will be Dr. Helen Torley, Halozyme's President and Chief Executive Officer, who will provide an update on our business; and Laurie Stelzer, our Chief Financial Officer, who will review our financial results for the second quarter 2019.

During the call, we will be making forward-looking statements. I refer you to our SEC filings for a full listing of the risks and uncertainties.

I'll now turn the call over to Helen.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot